Drugs for military special needs are important strategic materials for supporting military operational needs and maintaining national security,and are highly valued by Armed Forces in each country in the world.The U.S.military has accumulated much experience through the long-term management of drugs for military special needs.Here,The U.S.military and civilian integration management of drugs for military special needs between the U.S.DOD and FDA was analyzed in terms of research,purchase,use and storage,the secrets of success were summarized,and problems were identified.Finally,recommendations on military and civilian integration management of drugs for military special needs in China were proposed.

This paper summarizes the main methods of civil-military integration,academy of military medical sciences,analyzes the main problems restricting the development of military and civilian integration depth,puts forward to strengthen military medicine civil-military integration of science and technology innovation and development measures.

This paper introduced the feasibility of flexible management from medical scientific re-search institutions, embarks on the aspects of construction contents such as value identity system, fuzzy eval-uation system, sharing mechanism of scientific management aims and information involving in implementing management. And the paper combined with the experience of the innovation projects in Chinese Academy of Sciences and our institution, and preliminarily expounds the construction connotations and keys of the "flexi-ble management system" in medical scientific research units to provide ideas for enriching the management thoughts of medical scientific research.

Objective To cvaluate the efficacy and safety of HabibTM VesOpen intravascular radiofrequency catheter percutaneous radiofrequency ablation combined with TACE in the treatment of portal vein tumor thrombus of primary hepatocellular carcinoma.Methods Thirty-nine patients with primary hepatocellular carcinoma complicated with portal vein thrombosis were treated with HabibTM VesOpen intracavitary catheter ablation combined with TACE.The postoperative success rate,complication,blood index,α-fetoprotein (AFP),portal vein patency and tumor thrombus imaging changes were assessed.Results All of 39 patients underwent surgery successfully without occurrence of perforation,infection,hepatapostema,intra-abdominal hemorrhage nor other complications associated with surgery.Blood routine examinations (WBC,RBC,PLT) after 2 weeks and 4 weeks of surgery had no statistical difference compared with those of preoperation.Liver function indexes including ALT,AST,ALB had statistical difference before and after the surgery except for TBIL.AFP had statistical difference before and after surgery.Doppler ultrasonography after 4 weeks showed blood flow in original blocked portal vein.Enhanced CT or MR examinations after 8 weeks on the abdomen,suggested that tumors were shrinked or disappeared.Conclusion Radiofrequency catheter ablation with intracavitary radiofrequency catheter of HabibTM VesOpen is an effective method in the treatment of portal vein tumor thrombus in primary hepatocellular carcinoma.

Radiation biodosimetry is an important part of radiation medicine. Some new discoveries and progresses have been made in radiation biodosimetry studies in recent years. Cytogenetic method represented by chromosome aberration analysis as the golden standard of radiation biodosimeter is being transformed to automate analysis, and a number of international, regional and national laboratory networks of radiation biodosimetry are being established. As a widely acceptable molecular marker of DNA damage,γ-H2AX has made rapid progress in radiation dose estimation. Based on the expressions of protein and genes, further advancements have been made in the studies of metabolites and miRNAs. At the same time, with the development of proteomics technology, there are some breakthroughs in the study of using molecular expression profiling to evaluate radiation dose. The research progresses of radiation biodosimetry is reviewed in this paper.

Objective To clone the full-length CDS sequence of LOC 401296 , an undefined gene that we found recently, and to obtain both its expression in eukaryotic cells or E.coli and antiserum to LOC401296 protein.Methods The full-length CDS sequence of LOC401296 was amplified by polymerase chain reaction (PCR).Then we established the expression vectors pET28B-LOC401296 and pCMV-Myc-LOC401296 by cloning the full-length CDS sequence into vector PET28B and vector pCMV-Myc respectively.Isopropyl Thiogalactoside (IPTG) was used to induce LOC401296 expression in E.coli.Furthermore,the protein purified and refolded was used to immunize BALB /c mice.The titer of the antiserum collected from immunized mice was identified by ELISA assay and Western blot .Results We cloned the full-length CDS sequence of LOC401296 was successfully .Protein LOC401296 was expressed as was expected and the mouse anti-human LOC401296 antiserum was obtained .The antiserum titer reaching 1∶64 000 was identified by ELISA .Besides, Western blot analysis showed that the antiserum could be used to detect protein LOC 401296 .Conclusion The full-length sequence of LOC401296 is obtained and the mouse anti-human LOC401296 antiserum becomes available .This study can contribut to further research on the undefined gene LOC 401296 .

With the development of civil military integration,military scientific research institu tes are facing the challenge of constructing a new mode of translating scientific and technological achievements into practice and enhancing translational efficiency.This paper began with the evolution of translation mode in military institutes and discussed the flaws and insufficiency of current mode,then a triple helix translation mode,which encompass government,industry and research,was introduced and fully explained for future reference.

OBJECTIVETo evaluate the prognostic value of the lymph node ratio(LNR) staging system for rectal cancer following 30 Gy/10 f preoperative radiotherapy.

METHODSClinical data of 282 patients with mid-lower locally advanced rectal cancer who received preoperative radiotherapy and curative surgery in the Peking University Cancer Hospital from August 2003 to August 2009 were retrospectively reviewed. The radiotherapy regimen was recommended by CACA. Total dose of 30 Gy was divided into 10 fragments (30 Gy/10 f), the biologically equivalent dose (BED) was 36 Gy, and 3D conformal radiotherapy(3D-CRT) was used. Surgery was performed 2-4 weeks after radiation. The prognostic effect of the lymph node ratio(LNR) staging system in addition to the 7th AJCC staging system were retrospectively analyzed and compared in stage III( cases with positive lymph node(s). Patients were divided into four groups by LNR quantiles: LNR1(<0.070), LNR2(0.070-0.142), LNR3(0.143-0.307) and LNR4(>0.307).

RESULTSA total of 108 eligible cases were included in the study. The 3-year disease-free survival (3-yr DFS) was 61.1%. On univariate analysis, circumferential resection margin involvement(P=0.034), tumor differentiation (P=0.002), N stage (P=0.001), TNM stage(P=0.000) and LNR(P=0.003) were significantly associated with 3-yr DFS. On multivariate analysis, abdominoperineal resection (P=0.006, HR=2.611, 95%CI:1.323-5.153), G3-4 differentiation (P=0.015, HR=2.208, 95%CI:1.163-4.192), ypN2a/N2b stage(as covariate: P=0.024, HR=2.568, 95%CI:1.135-5.810; P=0.001, HR=3.759, 95%CI:1.776-7.958) were independent risk factors for decreased 3-yr DFS. Other factors including LNR were excluded in Cox regression model. The 3-yr DFS was statistically different among subcategories of ypN stage. There was no statistical difference of 3-yr DFS in pair-wise comparison of LNR1 and LNR2, LNR2 and LNR3 and LNR3 and LNR4. Additional use of LNR over AJCC staging system did not improve the prediction of prognosis for III(B/C stages and for each stratum of ypN stages, despite the prognostic separation by LNR in III(A stage.

CONCLUSIONThe LNR staging system in addition to the 7th AJCC staging system does not provide further detailed stratification of the prognosis for stage III( rectal cancer following 30 Gy/10 f preoperative radiotherapy. Lymph node ratio is premature as a prognostic factor in clinical practice.

Disease-Free Survival ; Humans ; Lymphatic Metastasis ; Multivariate Analysis ; Neoplasm Staging ; Prognosis ; Rectal Neoplasms ; pathology ; radiotherapy ; surgery ; Retrospective Studies

Objective To evaluate the value of dual-source CT angiography for evaluating the degree of coronary stenosis. Methods A total of 110 patients with a high likelihood of coronary stenosis identified by dual-source CT angiography or conventional coronary angiography were enrolled. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of dual-source CT angiography for diagnosis of coronary stenosis were evaluated with conventional coronary angiography as a gold standard. The agreement between dual-source CT angiography and conventional coronary angiography for evaluation of coronary stenosis was evaluated using Kappa statistic. Results A total of 1 401 coronary artery segments from 110 patients were displayed on conventional coronary angiography, while 1 382 segments were successfully visualized in dual-source CT angiography (98.64%). The sensitivity, specificity, positive predictive value and negative predictive value of dual-source CT angiography were 97.9%, 97.3%, 90.4% and 99.4% for diagnosis of coronary stenosis, and there was high consistence between dual-source CT angiography and conventional coronary angiography for grading coronary stenosis (Kappa statistic = 0.87, U = 58.36, P < 0.01). In addition, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of dual-source CT angiography were 94.7%, 96.8%, 83.7%, 99.0% and 96.5% for grading stenosis of coronary artery segments. Conclusion Dual-source CT angiography is accurate and reliable for diagnosis of coronary stenosis, which may be a non-invasive tool for assessment of coronary stenosis.

OBJECTIVE: To assess the effect of tumor cell lysate (TCL) with low high-mobility group B1 (HMGB1) content for enhancing immune responses of dendritic cells (DCs) against lung cancer. METHODS: TCLs with low HMGB1 content (LH-TCL) and normal HMGB1 content (NH-TCL) were prepared using Lewis lung cancer (LLC) cells in which HMGB1 was inhibited with 30 nmol/L glycyrrhizic acid (GA) and using LLC cells without GA treatment, respectively. Cultured mouse DCs were exposed to different doses of NH-TCL and LH-TCL, using PBS as the control. Flow cytometry was used to detect the expressions of CD11b, CD11c and CD86 and apoptosis of the stimulated DCs, and IL-12 levels in the cell cultures were detected by ELISA. Mouse spleen cells were co-cultured with the stimulated DCs, and the activation of the spleen cells was assessed by detecting CD69 expression using flow cytometry; TNF-β production in the spleen cells was detected with ELISA. The spleen cells were then co-cultured with LLC cells at the effector: target ratios of 5:1, 10:1 and 20:1 to observe the tumor cell killing. In the animal experiment, C57/BL6 mouse models bearing subcutaneous LLC xenograft received multiple injections with the stimulated DCs, and the tumor growth was observed. RESULTS: The content of HMGB1 in the TCL prepared using GA-treated LLC cells was significantly reduced (P < 0.01). Compared with NH-TCL, LH-TCL showed a stronger ability to reduce apoptosis (P < 0.001) and promote activation and IL- 12 production in the DCs. Compared with those with NH-TCL stimulation, the DCs stimulated with LH-TCL more effectively induced activation of splenic lymphocytes and enhanced their anti-tumor immunity (P < 0.05). In the cell co-cultures, the spleen lymphocytes activated by LH-TCL-stimulated DCs showed significantly enhanced LLC cell killing activity (P < 0.01). In the tumor-bearing mice, injections of LH-TCL-stimulated DCs effectively activated host anti-tumor immunity and inhibited the growth of the tumor xenografts (P < 0.05). CONCLUSION Stimulation of the DCs with LH-TCL enhances the anti-tumor immune activity of the DCs and improve the efficacy of DCbased immunotherapy for LLC in mice.
Animals ; Humans ; Mice ; Apoptosis ; Dendritic Cells/immunology* ; Glycyrrhizic Acid/pharmacology* ; HMGB1 Protein ; Lung Neoplasms/immunology*